Evidence map›Paper›PMID 39135088›Full record

ReviewStem cell research & therapy2024

Examining the potentials of stem cell therapy in reducing the burden of selected non-communicable diseases in Africa.

Faith Ayobami Atewologun, Olalekan John Okesanya, Inibehe Ime Okon, Hassan Hakeem Kayode, Bonaventure Michael Ukoaka, Noah Olabode Olaleke, Jerico Bautista Ogaya, Lawal Azeez Okikiola, Emery Manirambona, Don Eliseo Lucero-Prisno Iii

Abstract readReview
In one paragraph

Review in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Faith Ayobami AtewologunDepartment of Medicine and Surgery, Ladoke Akintola University of Technology, Ogbomoso, Nigeria.
Olalekan John OkesanyaFaculty of Laboratory Hygiene and Epidemiology, University of Thessaly, Volos, Greece.
Inibehe Ime OkonDepartment of Research, Medical Research Circle (MedReC), Democratic Republic of the Congo, Postal Code 50 Goma, Bukavu, Democratic Republic of Congo. inibeheokon3@gmail.com.ORCID 0009-0003-8275-5713
Hassan Hakeem KayodeDepartment of Medical Laboratory Science, Federal Medical Centre, Bida, Niger State, Nigeria.
Bonaventure Michael UkoakaDepartment of Internal Medicine, Asokoro District Hospital, Abuja, Nigeria.
Noah Olabode OlalekeObafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Osun State, Nigeria.
Jerico Bautista OgayaDepartment of Medical Technology, Far Eastern University, Manila, Philippines.
Lawal Azeez OkikiolaDepartment of Biology, University of Texas at Tyler, Tyler, USA.
Emery ManirambonaCollege of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.
Don Eliseo Lucero-Prisno IiiDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell therapy (SCT) is a promising solution for addressing health challenges in Africa, particularly non-communicable diseases (NCDs). With their regenerative potential, stem cells have the inherent capacity to differentiate into numerous cell types for tissue repair. Despite infrastructural, ethical, and legal challenges, SCT holds immense promise for managing chronic illnesses and deep-seated tissue injuries. The rising prevalence of NCDs in Africa highlights the need for innovative strategies and treatment options. SCT offers hope in combating conditions like burns, osteoarthritis, diabetes, Alzheimer's disease, stroke, heart failure and cancer, potentially reducing the burden of NCDs on the continent. Despite SCT's opportunities in Africa, there are significant obstacles. However, published research on SCT in Africa is scarce, but recent initiatives such as the Basic School on Neural Stem Cells (NSC) express interest in developing NSC research in Africa. SCT research in African regions, notably on neurogenesis, demonstrates a concentration on studying neurological processes in indigenous settings. While progress has been made in South Africa and Nigeria, issues such as brain drain and impediments to innovation remain. Clinical trials have investigated the efficacy of stem cell treatments, emphasising both potential benefits and limitations in implementing these therapies efficiently. Financing research, developing regulatory frameworks, and resolving affordability concerns are critical steps toward realizing the potential of stem cell treatment in Africa.

Indexed as

Noncommunicable DiseasesStem Cell TransplantationAfricaCell- and Tissue-Based TherapyHumansCell-based therapyHematopoietic stem cells (HSCs)Mesenchymal stem cells (MSCs)Neural stem cells (NSC)Pluripotent stem cells (PSCs)Regenerative medicineStem cell therapy (SCT)

Identifiers

PMID39135088
PMCPMC11321202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.